SCHEMBL295346

SCHEMBL295346

COc1ccc(CN)c(N)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
MEN1 O00255 2/20 0.53
MAPT P10636 2/20 0.53
THRB P10828 2/20 0.53
KMT2A Q03164 2/20 0.53
TDP1 Q9NUW8 3/20 0.52
KDM4E B2RXH2 1/20 0.52
GAA P10253 1/20 0.52
RECQL P46063 1/20 0.52
BLM P54132 1/20 0.52
MCL1 Q07820 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HTR2B P41595 1/20 0.50
CYP3A4 P08684 3/20 0.48
ADRA1A P35348 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
APLNR P35414 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.43
IDO1 P14902 2/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4852727 0.85 ALDH1A1 (0.55) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL5217973 0.84 TAAR1 (0.62) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL774393 0.83 ALDH1A1 (0.53) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL706675 0.82 ALDH1A1 (0.55) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL11782724 0.82 ALDH1A1 (0.52) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL12801460 0.80 ALDH1A1 (0.50) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL3816078 0.80 ALDH1A1 (0.50) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL153750 0.79 APLNR (0.63) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL29350908 0.79 APLNR (0.63) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL20446477 0.79 HTR2B (0.50) MAPTHTR2BADRA1ATAAR1APLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2391626-B1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS Univerzita Palackého v Olomouci (CZ) 2014-10-01 EP disclosed
US-20140031334-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-30 US disclosed
US-8598162-B2 Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-12-03 US disclosed
CN-102850336-A DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMA CO LTD 2013-01-02 CN disclosed
CN-102702182-A Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders OTSUKA PHARMA CO LTD 2012-10-03 CN disclosed
CN-102558140-A Derivatives of 4-piperazin-1-1-yl-4-benzo [b] thiophene suitable for the treatment of cns disorders OTSUKA PHARMA CO LTD 2012-07-11 CN disclosed
EP-2287161-B1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders OTSUKA PHARMA CO LTD (JP) 2012-05-09 EP disclosed
EP-2287162-B1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders OTSUKA PHARMA CO LTD (JP) 2012-05-09 EP disclosed
CN-101258147-B 4-piperazin-1-yl-4-benzo [ B ] thiophene derivatives for the treatment of CNS disorders OTSUKA PHARMA CO LTD 2012-03-21 CN disclosed
EP-2284169-B1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders OTSUKA PHARMA CO LTD (JP) 2012-03-14 EP disclosed
CN-101835752-A Heterocyclic amides useful for the treatment of cancer and psoriasis ASTRAZENECA AB 2010-09-15 CN disclosed
CN-101668749-A Novel pyrimidine derivatives 698 ASTRAZENECA AB 2010-03-10 CN disclosed
US-20090264404-A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-10-22 US disclosed
CN-101258147-A 4-piperazin-1-yl-4-benzo [ B ] thiophene derivatives for the treatment of CNS disorders OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
US-7348332-B2 (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines HOFFMANN-LA ROCHSE INC. (US) 2008-03-25 US disclosed
US-7348332-B2 (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines HOFFMANN-LA ROCHSE INC. (US) 2008-03-25 US disclosed
US-7348332-B2 (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines HOFFMANN-LA ROCHSE INC. (US) 2008-03-25 US disclosed
EP-1871748-A1 (3,4-DIHYDRO-QUINAZOLIN-2-YL)-INDAN-1-YL-AMINES F. Hoffmann-Roche AG (CH) 2008-01-02 EP disclosed
WO-2006108773-A1 (3,4-DIHYDRO-QUINAZOLIN-2-YL)-INDAN-1-YL-AMINES F. HOFFMANN-LA ROCHE AG (CH) 2006-10-19 WO disclosed
US-20060229323-A1 (3,4-Dihydro-quinazolin-2-yl)-indan-1-yl-amines F. HOFFMANN-LA ROCHE AG (CH) 2006-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229323-A1 (3,4-Dihydro-quinazolin-2-yl)-indan-1-yl-amines HTR5A, HTR1A, HTR1E ALDH1A1 281/4885MEN1 2152/4885MAPT 3570/4885
US-20140031334-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS GRIN2C, GRIN2B, PMP22 ALDH1A1 408/4885MEN1 2715/4885MAPT 223/4885
US-20090264404-A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders GRIN2C, GRIN2B, PMP22 ALDH1A1 408/4885MEN1 2715/4885MAPT 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.